201 related articles for article (PubMed ID: 1389934)
1. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.
Pöyhiä R; Seppälä T; Olkkola KT; Kalso E
Br J Clin Pharmacol; 1992 Jun; 33(6):617-21. PubMed ID: 1389934
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat.
Chan S; Edwards SR; Wyse BD; Smith MT
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):295-302. PubMed ID: 17973932
[TBL] [Abstract][Full Text] [Related]
3. Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases.
Pantano F; Brauneis S; Forneris A; Pacifici R; Marinelli E; Kyriakou C; Pichini S; Busardò FP
Clin Chem Lab Med; 2017 Aug; 55(9):1324-1331. PubMed ID: 28080998
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation.
Kirvela M; Lindgren L; Seppala T; Olkkola KT
J Clin Anesth; 1996 Feb; 8(1):13-8. PubMed ID: 8695073
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
[TBL] [Abstract][Full Text] [Related]
6. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.
Fang WB; Lofwall MR; Walsh SL; Moody DE
J Anal Toxicol; 2013; 37(6):337-44. PubMed ID: 23743505
[TBL] [Abstract][Full Text] [Related]
7. The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue.
Boström E; Jansson B; Hammarlund-Udenaes M; Simonsson US
Rapid Commun Mass Spectrom; 2004; 18(21):2565-76. PubMed ID: 15468158
[TBL] [Abstract][Full Text] [Related]
8. Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.
Kokki H; Rasanen I; Lasalmi M; Lehtola S; Ranta VP; Vanamo K; Ojanperä I
Clin Pharmacokinet; 2006; 45(7):745-54. PubMed ID: 16802855
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of oxycodone after intravenous injection in adults.
Pöyhiä R; Olkkola KT; Seppälä T; Kalso E
Br J Clin Pharmacol; 1991 Oct; 32(4):516-8. PubMed ID: 1958450
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
Leuppi-Taegtmeyer A; Duthaler U; Hammann F; Schmid Y; Dickenmann M; Amico P; Jehle AW; Kalbermatter S; Lenherr C; Meyer Zu Schwabedissen HE; Haschke M; Liechti ME; Krähenbühl S
Nephrol Dial Transplant; 2019 Apr; 34(4):692-702. PubMed ID: 30189012
[TBL] [Abstract][Full Text] [Related]
11. Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry.
Gaudette F; Sirhan-Daneau A; St-Onge M; Turgeon J; Michaud V
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1008():174-180. PubMed ID: 26655109
[TBL] [Abstract][Full Text] [Related]
12. Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine.
Moy KV; Ma JD; Morello CM; Atayee RS; Best BM
J Opioid Manag; 2014; 10(1):47-56. PubMed ID: 24604569
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of oxycodone hydrochloride and three of its metabolites after intravenous administration in Chinese patients with pain.
Hao GT; Zhou HY; Gao HZ; Qu HY; Liang YG; Li YY; Dong RH; Zhang LJ; Wang XF; Liu ZY
Pharmacol Rep; 2014 Feb; 66(1):153-8. PubMed ID: 24905321
[TBL] [Abstract][Full Text] [Related]
14. Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry.
Neuvonen M; Neuvonen PJ
Ther Drug Monit; 2008 Jun; 30(3):333-40. PubMed ID: 18520605
[TBL] [Abstract][Full Text] [Related]
15. Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration.
Cone EJ; Heltsley R; Black DL; Mitchell JM; Lodico CP; Flegel RR
J Anal Toxicol; 2013 Jun; 37(5):255-64. PubMed ID: 23609023
[TBL] [Abstract][Full Text] [Related]
16. Observations of urinary oxycodone and metabolite distributions in pain patients.
Elder NM; Atayee RS; Best BM; Ma JD
J Anal Toxicol; 2014 Apr; 38(3):129-34. PubMed ID: 24523296
[TBL] [Abstract][Full Text] [Related]
17. Grapefruit juice enhances the exposure to oral oxycodone.
Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):782-8. PubMed ID: 20406214
[TBL] [Abstract][Full Text] [Related]
18. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
[TBL] [Abstract][Full Text] [Related]
19. A sensitive LC-MS/MS method for the quantitation of oxycodone, noroxycodone, 6α-oxycodol, 6β-oxycodol, oxymorphone, and noroxymorphone in human blood.
Truver MT; Jakobsson G; Chermà MD; Swortwood MJ; Gréen H; Kronstrand R
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 May; 1171():122625. PubMed ID: 33744597
[TBL] [Abstract][Full Text] [Related]
20. Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
Fujiwara Y; Toyoda M; Chayahara N; Kiyota N; Shimada T; Imamura Y; Mukohara T; Minami H
PLoS One; 2014; 9(8):e104215. PubMed ID: 25121773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
